8 recruiting, 2 not yet recruiting, 1 completed. 11 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 8, Not yet recruiting 2, Completed 1 |
| Phase 1 | 5 | Not yet recruiting 2, Recruiting 2, Completed 1 |
Follow T-cell Acute Lymphoblastic Leukemia: new trials by email Literature Review of T-cell Acute Lymphoblastic Leukemia trials Research Report on T-cell Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-11-02 |
| A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Autologous nano CD5-CAR T Cells - T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2026-06-30 | 2026-07-01 |
| A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) Decitabine, Venetoclax, Calaspargase pegol-mknl - T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 22 | 2025-09-25 | 2026-09-18 |
| A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) WU-CART-007 - T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Recruiting | Allotera Therapeutics | 125 | 2025-01-31 | 2026-09-28 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 100 | 2024-12-27 | 2026-08-10 |
| Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax - T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 59 | 2024-10-30 | 2025-05-07 |
| Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells CD5/CD7 CAR-T - T Cell Lymphoma, T Cell Leukemia | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2024-07-10 | 2024-11-12 |
| Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell - T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 80 | 2024-03-22 | 2025-11-26 |
| Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL Daratumumab / Hyaluronidase Injection - T-cell Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Eastern Cooperative Oncology Group | 20 | 2023-05-25 | 2026-11-16 |
| Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients Venetoclax, Azacitidine - T-cell Acute Lymphoblastic Leukemia, Recruiting | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 28 | 2022-04-01 | 2026-03-19 |
| A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL LY3039478, Dexamethasone, Placebo - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 36 | 2015-10-01 | 2019-09-11 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (11) · Lymphoma, T-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic, T-Cell (1) · Leukemia, T-Cell (1) · Recurrence (1)
Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Leukemia, Lymphoid (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Leukemia (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Disease Attributes (1) · Leukemia, Myeloid (1)
venetoclax (4) · Azacitidine (2) · Decitabine (2) · Dexamethasone (2) · calaspargase pegol (2) · Bortezomib (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Cytarabine (1) · Dasatinib (1) · Daunorubicin (1) · Hyaluronoglucosaminidase (1) · Hydrocortisone (1) · Mercaptopurine (1) · Methotrexate (1)
Allotera Therapeutics (1) · Beijing GoBroad Hospital (1) · Eastern Cooperative Oncology Group (1) · Eli Lilly and Company (1) · Essen Biotech (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · M.D. Anderson Cancer Center (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Shenzhen Geno-Immune Medical Institute (1) · St. Jude Children's Research Hospital (1) · The First Affiliated Hospital of Soochow University (1)
China (5) · United States (5) · Australia (1) · France (1) · Germany (1) · Israel (1) · Italy (1)
Cherry Thomas, MD (1) · David McCall, MD (1) · Seth E. Karol, MD, MSCI (1) · Shira Dinner, MD (1)
2014 (1)